ImmunityBio, Inc. remains a Buy, with Anktiva’s regulatory and global expansion driving the investment thesis. Learn more ...
ImmunityBio Inc. IBRX shares are up Tuesday following the announcement that the National Comprehensive Cancer Network (NCCN) has updated its Clinical Practice Guidelines in Oncology for Bladder Cancer ...
The company now expects a longer path to approval than anticipated, leading it to deprioritize a therapy billed as a threat to Pfizer’s fast-selling bladder cancer drug.
Medindia on MSN
Blood in urine? Why early scans detect bladder cancer faster
India, March 17 -- Latest study shows a serious link between emergency room wait times and patient survival. One in ten accident and emergency patients (A&E patients) with visible blood in urine ...
ImmunityBio (IBRX) stock jumped over 6% in premarket trading after the NCCN added ANKTIVA to its bladder cancer guidelines, expanding its use.
ImmunityBio (IBRX) stock jumps as NCCN guidelines recommend an additional use for the company's bladder cancer therapy, Anktiva. Read more here.
Life-saving treatments for children with orphan illnesses often move slowly, if at all, through the federal approval process.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results